4DMedical Posts 56% Revenue Growth, Secures $10m Pro Medicus Investment

Strong Financial Momentum and SaaS Expansion

4DMedical Limited (ASX, 4DX) has delivered a compelling FY2025 performance, posting a 56% increase in operating revenue to $5.9 million, underpinned by a near doubling of its Software-as-a-Service (SaaS) income. The company’s SaaS offerings now reach 388 clinical sites globally, a 60% increase year-on-year, reflecting growing adoption of its advanced respiratory imaging technologies.

This growth was achieved alongside a strategic cost reduction program initiated in Q3 FY2025, which has already generated $6.5 million in annualised savings, enabling 4DMedical to focus resources on revenue-generating activities without compromising its innovation pipeline.

FDA Submission Marks a Milestone for CT, VQ™

In a significant regulatory milestone, 4DMedical filed its FDA 510(k) submission for CT, VQ™ in May 2025. This novel software offers non-contrast, CT-based ventilation and perfusion lung imaging, addressing critical limitations of existing modalities by eliminating the need for radiotracers or contrast agents. The technology promises to streamline workflows and improve accessibility, leveraging the extensive installed base of CT scanners across the US healthcare system.

CT, VQ™ is positioned to disrupt a market currently dominated by nuclear ventilation-perfusion scans, valued at over USD $1.1 billion annually in the US alone. Early clinical adoption at prestigious institutions such as Stanford University and Brooke Army Medical Center underscores its potential impact.

Strategic Partnerships Fuel Market Penetration

4DMedical’s commercial momentum is further bolstered by a $10 million strategic investment from Pro Medicus, a global leader in medical imaging software. Additionally, a landmark reseller agreement with Philips has integrated 4DMedical’s product suite into Philips’ catalogue, granting Philips exclusive rights to distribute to US government customers, including the Department of Veterans Affairs and Department of Defense.

This partnership leverages Philips’ extensive network and longstanding relationships within the US government healthcare sector, accelerating 4DMedical’s reach into critical markets. Philips’ senior leadership has publicly advocated for the technology’s potential to modernize veteran healthcare, highlighting the strategic depth of this collaboration.

Clinical Validation and Global Footprint Expansion

Scientific validation continues to support 4DMedical’s technology, with recent peer-reviewed studies demonstrating the clinical utility of its XV Technology® in detecting subtle lung diseases often missed by conventional tests. This evidence base strengthens the company’s position as a leader in respiratory diagnostics.

Commercially, 4DMedical has secured new contracts with leading US academic medical centers such as UChicago Medicine and UCSD Health, alongside renewals at Cleveland Clinic, Stanford University, and University of Michigan. In Australia, partnerships with Integral Diagnostics, QScan, and Perth Radiological Clinic have expanded the company’s footprint, enhancing access to advanced lung imaging for patients nationwide.

Outlook

With a strong balance sheet bolstered by recent investments and expected R&D tax credits, 4DMedical is well-positioned to capitalize on the anticipated FDA clearance of CT, VQ™ and the accelerating commercial uptake of its SaaS products. The company’s focus on scalable, cost-efficient operations alongside strategic partnerships sets the stage for sustained growth into FY2026 and beyond.